Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development.
Theranostics
; 14(8): 3300-3316, 2024.
Article
in En
| MEDLINE
| ID: mdl-38855182
ABSTRACT
Patient-derived organoids (PDOs) have emerged as a promising platform for clinical and translational studies. A strong correlation exists between clinical outcomes and the use of PDOs to predict the efficacy of chemotherapy and/or radiotherapy. To standardize interpretation and enhance scientific communication in the field of cancer precision medicine, we revisit the concept of PDO-based drug sensitivity testing (DST). We present an expert consensus-driven approach for medication selection aimed at predicting patient responses. To further standardize PDO-based DST, we propose guidelines for clarification and characterization. Additionally, we identify several major challenges in clinical prediction when utilizing PDOs.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Organoids
/
Consensus
/
Precision Medicine
/
Drug Development
/
Neoplasms
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
Theranostics
Year:
2024
Document type:
Article